Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Defence Therapeutics Inc (DTC.CN)
Defence Therapeutics Inc (DTC.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 86,597
  • Shares Outstanding, K 44,869
  • Annual Sales, $ 0 K
  • Annual Income, $ -7,344 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade DTC.CN with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.19
  • Most Recent Earnings $-0.05 on N/A
  • Latest Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Biotechnology

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.7000 +8.82%
on 02/27/24
2.3200 -20.26%
on 02/01/24
-0.2000 (-9.76%)
since 01/26/24
3-Month
1.6600 +11.45%
on 01/22/24
2.8500 -35.09%
on 12/08/23
-0.8000 (-30.19%)
since 11/27/23
52-Week
1.6600 +11.45%
on 01/22/24
3.9600 -53.28%
on 03/21/23
-2.0200 (-52.20%)
since 02/27/23

Most Recent Stories

More News
Defence Therapeutics Completes 1st Tranche of Financing

Vancouver, British Columbia--(Newsfile Corp. - January 30, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnology...

DTCFF : 1.3550 (-5.24%)
DTC.CN : 1.8500 (-4.15%)
Defence Financing

Vancouver, British Columbia--(Newsfile Corp. - January 19, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnology...

DTCFF : 1.3550 (-5.24%)
DTC.CN : 1.8500 (-4.15%)
Defence Begins Trading on the OTCQB and Arranges Financing

Vancouver, British Columbia--(Newsfile Corp. - January 12, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), one of the leading Canadian biotechnology...

DTCFF : 1.3550 (-5.24%)
DTC.CN : 1.8500 (-4.15%)
Defence's AccuTOX(R) Impairs Lung Cancer Growth

Vancouver, British Columbia--(Newsfile Corp. - January 10, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), one of the leading Canadian biotechnology...

DTCFF : 1.3550 (-5.24%)
DTC.CN : 1.8500 (-4.15%)
RETRANSMISSION: Defence Receives FDA Approval for Phase I Clinical Trial Targeting Solid Cancer Tumors with AccuTOX(R)

Vancouver, British Columbia--(Newsfile Corp. - December 12, 2023) - Defence Therapeutics Inc. (CSE: DTC) (OTC Pink: DTCFF) (FSE: DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnology...

DTCFF : 1.3550 (-5.24%)
DTC.CN : 1.8500 (-4.15%)
Defence Receives FDA Approval for Phase I Clinical Trial Targeting Solid Cancer Tumors with AccuTOX(R)

Vancouver, British Columbia--(Newsfile Corp. - December 11, 2023) - Defence Therapeutics Inc. (CSE: DTC) (OTC Pink: DTCFF) (FSE: DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnology...

DTCFF : 1.3550 (-5.24%)
DTC.CN : 1.8500 (-4.15%)
Precision Medicine Helps Conquer Advanced-Stage Cancer

As North America reports a dramatic rise in advanced-stage cancer cases, experts are saying that major breakthroughs in oncology could make “now the best time in human history to get cancer.” According...

DTC.CN : 1.8500 (-4.15%)
Defence’s Successful Submission of an Investigational New Drug (IND) Application for AccuTOX(R) as an Injectable Anticancer Treatment for Solid Tumors

(November 14, 2023) - Defence Therapeutics Inc. (CSE:DTC) (OTC Pink:DTCFF) (FSE:DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnology companies working in

DTC.CN : 1.8500 (-4.15%)
DTCFF : 1.3550 (-5.24%)
Global Oncology Drugs Market Size Projected to Reach $484 Billion by 2030

EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NYSE:BMY),(NYSE:NVS),(NYSE:MRK),(OTCQX:RHHBY) EQNX::TICKER_END

DTCFF : 1.3550 (-5.24%)
DTC.CN : 1.8500 (-4.15%)
BMY : 50.50 (-0.02%)
NVS : 103.57 (+0.41%)
MRK : 130.00 (+0.75%)
RHHBY : 33.0300 (+1.57%)
Defence's Successful Submission of an Investigational New Drug (IND) Application for AccuTOX(R) as an Injectable Anticancer Treatment for Solid Tumors

Vancouver, British Columbia--(Newsfile Corp. - November 14, 2023) - Defence Therapeutics Inc. (CSE: DTC) (OTC Pink: DTCFF) (FSE: DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnology...

DTCFF : 1.3550 (-5.24%)
DTC.CN : 1.8500 (-4.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 2.1833
2nd Resistance Point 2.0567
1st Resistance Point 1.9533
Last Price 1.8500
1st Support Level 1.7233
2nd Support Level 1.5967
3rd Support Level 1.4933

See More

52-Week High 3.9600
Fibonacci 61.8% 3.0814
Fibonacci 50% 2.8100
Fibonacci 38.2% 2.5386
Last Price 1.8500
52-Week Low 1.6600

See More

Business Summary

Defence Therapeutics Inc is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The Company has one operating segment, being research...

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar